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In 2004, the Scottish Government recognised that “Hepatitis C 
is one of the most serious and significant public health risks of our 
generation” [1] . By December 2006, Health Protection Scotland 
(HPS) estimated that 50,000 people in Scotland had been infected 
with the hepatitis C virus (HCV) and that 38,000 were chronic 
carriers (Figure 1) [2]. Following an extensive consultation in 2005, 
the Health Minister and Chief Medical Officer launched Scotland’s 
‘Action Plan for Hepatitis C’ in September 2006 [3].
Its aims are:
• To prevent the spread of hepatitis C, particularly among 
intravenous drug users (IDUs); 
• To diagnose hepatitis C-infected people, particularly those who 
would most benefit from treatment; and 
• To ensure that those infected receive optimal treatment, care 
and support.
The plan is a two-phased one. Phase I, undertaken during 
September 2006 to March 2008, involved increasing awareness 
about hepatitis C among professionals and gathering evidence 
through numerous surveys and other investigations to inform 
proposals for the development of hepatitis C services during Phase 
II (2008-2011)[4]. This paper presents the key findings of the 
evidence gathering exercise, recommended actions stemming from 
the evidence and funding associated with the actions[5]. 
Phase I
Phase I was co-ordinated by HPS. An Action Plan Co-ordinating 
Group (APCG), comprising representatives of key stakeholder 
groups, oversaw the implementation of the Action Plan; the APCG 
was supported by Working Groups corresponding to the three areas 
of i) Prevention, ii) Testing, Treatment, Care and Support and iii) 
Education, Training and Awareness-Raising. Each, during the first 
half of 2007, oversaw the implementation of actions involving the 
generation of evidence; during the second half, they translated the 
evidence into proposed key issues and actions. At a consultation 
event in October 2007, issues, evidence and proposed actions 
were presented to nearly 200 stakeholders who indicated their 
approval/disapproval through a digital voting system. The Working 
Groups modified the actions in accordance with the findings of the 
consultation and, by early 2008, they were approved by the APCG. 
Final approval by Scotland’s Minister of Public Health was given 
for the Phase II Plan to be launched on World Hepatitis Day, 19 
May, 2008 [5].
Approaches taken to generate the evidence
The approaches adopted to gather the evidence, involved self-
administered questionnaire surveys and face-to-face interviews with 
service providers, the analysis of existing data held on laboratory and 
clinical databases, examining scientific literature and undertaking 
analytical studies to estimate the current and future clinical and 
financial burden of hepatitis C-related disease in Scotland.
Key epidemiological data
• As of 2006, of an estimated 38,000 living persons in Scotland, 
chronically infected with hepatitis C, 14,500 have been 
diagnosed, 8,000 had attended specialist clinical services for 
chronic hepatitis C and around 2,000 had received antiviral 
therapy; an estimated 2,100 hepatitis C infected persons had 
progressed to and were living with, cirrhosis (Figure 1). 
• In 2006, an estimated 250 and 110 hepatitis C infected 
persons, respectively, developed cirrhosis and liver failure. 
• It was estimated that if 2,000 persons per year received antiviral 
therapy over the next two decades, 5,200 and 2,700 cases, 
respectively, of hepatitis C-related cirrhosis and liver failure 
would be prevented in the future. 
• Of 450 persons initiated on antiviral therapy during 2006, 
approximately 30 were prison inmates. 
• In Greater Glasgow and Clyde, the area in Scotland with the 
greatest number of IDUs, the incidence of hepatitis C is steady 
at 20-30 infections per 100 person years of injecting. 
• It is estimated that between 1,000 and 1,500 IDUs in Scotland 
are infected annually. 
Summary of evidence: Testing, Treatment, Care and Support
• In recent years, very considerable progress in developing high 
quality services for hepatitis C infected persons in Scotland 
has been made; there are, however, several issues which need 
to be addressed.
• Insufficient numbers of infected persons, particularly former 
IDUs, are diagnosed.
• Widespread variations in the clinical management of hepatitis 
C infected persons exist.
• The training of the hepatitis C workforce is sub-standard.
• There is a lack of integration among primary care, specialist, 
addiction, prison and social care services, resulting in many 
hepatitis C infected persons failing to complete a successful 
passage through the diagnostic, referral, treatment and care 
pathway.
• Insufficient numbers of infected persons are being administered 
antiviral treatment and resources, particularly for specialist 
clinical management and social care, including the support 
of persons journeying through the patient pathway, are 
inadequate.
 Summary of evidence: Prevention
• Since the late 1980s, services providing needle/syringes to 
IDUs have been developed; these have been highly effective in 
preventing the transmission of HIV among IDUs. In the context 
of the more infectious and more longstanding (in terms of 
prevalence) hepatitis C Virus, however, there are many issues 
which need to be addressed.
• Widespread variations exist in the provision of injection 
equipment and educational initiatives for IDUs to prevent 
hepatitis C transmission, due to gaps in co-ordination and 
guidance. 
• A high frequency of injection equipment sharing and incidence 
of hepatitis C among IDUs is observed.
• Opportunities to evaluate novel approaches to injection 
equipment provision in community and prison settings exist.
• A dearth of hepatitis C information provision for young people 
in educational settings is evident.
Summary of proposed actions stemming from the above 
evidence
• Networks will be established, guidelines and standards 
produced and plans developed to ensure that approaches to the 
prevention, and diagnosis and care of persons with, hepatitis C 
are highly effective and, where appropriate, consistent.
• Initiatives to train the workforce in, and educate young people 
about, hepatitis C will be implemented and awareness-raising 
campaigns to promote hepatitis C testing will be undertaken.
• To reduce the numbers of hepatitis C infected persons who will 
progress to severe liver disease, services in both health and 
prison settings will be improved to increase the annual numbers 
of persons of individuals receiving therapy from 450 in 2006 
to 1,500 in 2010/11.
• To reduce hepatitis C transmission among IDUs, the nature, 
quantity and quality of services providing injection equipment, 
including paraphernalia other than needles and syringes, will 
be improved.
• To ensure that the performance of the above measures is 
monitored, several information generating initiatives (e.g. 
clinical databases, surveys gauging HCV incidence among IDUs) 
will be established or further developed.
Conclusions/Actions
Thirty-five recommended actions were submitted by the APCG to 
the Scottish Government for approval. All but one proposed action 
– the evaluation of community-based needle/syringe dispensing 
machines for IDUs – were approved by the Health Minister. £43.2 
million has been made available over three years, commencing 
May 2008; £36.7 million will be allocated to Scotland’s 14 Health 
Boards for the development of prevention, testing, treatment, 
care and support services. The Plan is designed to improve all 
hepatitis C services ranging from those that provide education 
to young people in schools about the dangers of drug use to the 
treatment of infected persons and the associated social support 
required to support them and their families through what, often, is a 
challenging journey. The Plan also recognises the crucial role of the 
voluntary and local authority sectors in providing education, training 
and social support services and the huge opportunity for hepatitis 
C-related prevention, diagnosis and treatment in Scotland’s prisons. 
A range of performance indicators will be adopted to monitor the 
performance of the Action Plan which will be co-ordinated, on behalf 
of the Scottish Government, by Health Protection Scotland.
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Ever Received Antiviral Treatment
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1IDU: Injecting Drug User
2Includes those who have cleared Hepatitis C from therapy
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